Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression.
Davy DengLubna HammoudehGilbert YoussefYu-Hui ChenKee-Young ShinMary Jane Lim-FatJose Ricardo McFaline-FigueroaUgonma N ChukwuekeShyam TanguturiDavid A ReardonEudocia Q LeeLakshmi NayakWenya Linda BiOmar ArnaoutKeith L LigonPatrick Yung WenRifaquat RahmanPublished in: Neuro-oncology advances (2023)
High NLR is associated with worse outcomes in newly diagnosed and recurrent glioblastoma. Appropriate eligibility criteria and accounting and reporting of blood-based biomarkers are important in the design and interpretation of newly diagnosed and recurrent glioblastoma trials.